

## ONIVYDE PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)				Provider Information (required)			
Date:				Provider Name:			
Patient Name:				Specialty:	NPI:		
Date of Birth:		Sex: □Male □Female		Office Phone:	Office Fax:		
Street Address:				Office Street Address:			
City:		State:	Zip:	City:	State:	Zip:	
Patient ID: <b>R</b>	1 1		1	Physician Signature:	<u>I</u>		
.11		P	HYSICIAN (	COMPLETES			
			Oniv	vyde			
		(i	rinotecan lipo	some injection)			
	**Check	www.fepblue.org/forn	nulary to confirm	which medication is part of the pati	ent's benefit		
		NOTE: Form m	ust be complete	ed in its entirety for processing	2		
Is this request for	brand or generic	? □Brand □Ge	eneric				
Does the patie	ent have a diagnos	sis of metastatic pa	ncreatic adeno	carcinoma? □Yes □No			
•		•					
2. Will complete	blood counts be	evaluated at Day 1	and Day 8 of o	each cycle? □Yes □No			
3. Does the prese	criber agree to wi	thhold Onivyde if	patient experie	nces diarrhea Grade 2-4 severi	ty? □Yes □N	lo	
4. Does the preso	criber agree to mo	onitor the patient's	neutrophil cou	nt before each dose? □Yes □	⊒No		
5. Does the patie	ent have a bowel of	obstruction? □Ye	s 🗖No				
6. Does the patie	ent have a diagnos	sis of clinically sig	nificant (sympt	tomatic or debilitating) interstit	tial lung disease	(ILD)? □Yes □No	
7. FEMALE Pa	tient: Is the patie	nt of reproductive	potential?	′es* □No			
	ill the patient be a	-	-	tion during treatment with Oni	vyde and for 7 m	onths after the last	
8. Is this request	for <b>INITIATIO</b>	N or CONTINUA	TION of thera	py? Please select answer below	v:		
	10.1	ease answer the fo	0 1				
		used as first-line tr		es*	nd laucovarin? [	JVos □No	
•				g gemcitabine-based therapy?		lies uno	
				ith fluorouracil and leucovoring		)	
•				han or equal to $1500/\text{mm}^3$ ?			
-		• •	, •	the following questions:			
a. Has the	e patient experien	ced disease progre	ession or unacce	eptable toxicity while on the re	quested therapy?	? □Yes □No	

b. Will this medication be used in combination with fluorouracil and leucovorin? □Yes □No



## **ONIVYDE**

Send completed form to: Service Benefit Plan **Prior Approval** P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 **Attn. Clinical Services** Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls.  Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA.</b>
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service.  The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed.  Please only fax the completed form once as duplicate submissions may delay processing times.

faster... Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA. Sign up today!

CVS/caremark